Exclusion criteria:~* Any evidence of a condition other than AD that may affect cognition~* History of
schizophrenia, schizoaffective disorder, major depression, or bipolar disorder~* History or presence of
clinically evident systemic vascular disease that in the opinion of the investigator has the potential to
affect cognitive function~* History or presence of clinically evident cerebrovascular disease~* History or
presence of posterior reversible encephalopathy syndrome~* History or presence of any stroke with clinical
symptoms within the past 12 months, or documented history within the last 6 months of an acute event that is
consistent with a transient ischemic attack~* History of severe, clinically significant CNS trauma~* History or
presence of intracranial mass (e.g., glioma, meningioma) that could potentially impair cognition~* Presence of
infections that affect brain function or history of infections that resulted in neurologic sequelae~* History
or presence of systemic autoimmune disorders that potentially cause progressive neurologic disease with
associated cognitive deficits~* At risk for suicide in the opinion of the investigator~* Alcohol and/or
substance abuse or dependants in past 2 years~* Relevant brain hemorrhage, bleeding disorder and
cerebrovascular abnormalities~* Any contraindications to brain MRI~* Unstable or clinically significant
cardiovascular, kidney or liver disease~* Uncontrolled hypertension~* Unstable or clinically significant
cardiovascular disease~* Abnormal thyroid function~* Patients with evidence of folic acid deficiency~Exclusion
for Open-Label Extension (OLE):~* Discontinued from study treatment during the double-blind treatment period~*
Received any other investigational medication during the double-blind treatment period or after the end of
double-blind treatment~* Participation in the OLE deemed inappropriate by the investigator~* Presence of ARIA-E
findings at the Week 116 MRI scan
